Insilico Medicine’s Generative AI-designed Drug ISM001-055 Shows Promising Results in Phase IIa Clinical Trials In a ...

MHRA and HREC authorization in Australia further expands and will potentially accelerate enrollment in ongoing U.S. and UK Phase 2a biomarker ...

Professor Alyn Morice will present an analysis of cough relief in patients with idiopathic pulmonary fibrosis who were treated with nalbuphine ER About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc ...

Interstitial Lung Disease (ILD) is a chronic condition marked by lung inflammation and scarring that makes breathing ...

Aileron Therapeutics completes patient enrollment in Cohort 2 of phase 1b trial of LTI-03 in idiopathic pulmonary fibrosis: Austin, Texas Wednesday, September 25, 2024, 15:00 Hrs ...

According to a ... Researchers Identify Protein Connected to Aging and Idiopathic Pulmonary Fibrosis July 25, 2022 — Idiopathic pulmonary fibrosis (IPF) is an aging-associated disease caused by ...

Desaturation during the 6-minute walk test is a significant predictive factor for mortality in patients with idiopathic pulmonary fibrosis.

Pulmonary Fibrosis Awareness Month may be coming to a close, but it's important to keep the momentum going, columnist Sam Kirton says.

Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five presentations and one poster across its commercial and development portfolio will be presented ...

On September 17, 2024, the lord blessed Randall “Randy” Scott Hall a much-deserved poetic exit, after an acute exacerbation of idiopathic pulmonary fibrosis (IPF), at Saint Joesph Hospital in Denver, ...

Insilico Medicine has made headlines for discovering novel compounds for fibrosis using AI-generated models, further ...